Welcome to our dedicated page for Catheter Precision news (Ticker: VTAK), a resource for investors and traders seeking the latest updates and insights on Catheter Precision stock.
Catheter Precision, Inc. (VTAK) is a U.S.-based medical device company focused on the cardiac electrophysiology market, and its news flow reflects developments around its VIVO 3D imaging system and LockeT suture retention device. The company’s releases highlight product adoption, regulatory milestones, financial updates, and corporate actions relevant to investors and clinicians following VTAK stock.
Recent news has emphasized international expansion for both VIVO and LockeT. Catheter Precision has reported tender wins and first purchase orders for the VIVO system at hospitals such as Albert Szent‑Györgyi Health Centre in Hungary and Dubrava University Hospital in Croatia, following evaluations against competing technologies. For LockeT, the company has announced launches in Switzerland and South Africa, distribution agreements with regional partners, and implementation at major electrophysiology centers, including Mater Private Hospital in Dublin, Ireland.
In addition to commercial updates, Catheter Precision issues releases on financial results, furnished on Form 8‑K, summarizing revenue trends and operating performance for specific quarters and year‑to‑date periods. The company also uses news announcements to discuss regulatory and reimbursement developments that may affect the use of its products, such as changes in procedure coverage for ambulatory surgery centers that it views as relevant to LockeT utilization.
Other news items cover intellectual property developments, including allowance of patents related to ventricular arrhythmia localization and neurostimulation devices, as well as corporate and capital markets events like reverse stock splits, at‑the‑market offering programs, and stockholder meetings. For ongoing insight into VTAK, this news page aggregates these updates so readers can follow Catheter Precision’s product adoption, geographic reach, financial disclosures, and key regulatory or governance events over time.
Catheter Precision (NYSE American:VTAK) has appointed Philip Anderson as its new Chief Financial Officer, replacing Interim CFO Margrit Thomassen, who will continue as Controller. CEO David Jenkins highlighted Anderson's diverse background in executive management, hedge fund partnership, and investment banking.
Anderson received an inducement award of options to purchase 500,000 shares of Company common stock at $0.53 per share, vesting monthly over three years with a 10-year term. The options were granted under NYSE American listed company manual Section 711(a).
Anderson expressed enthusiasm about joining VTAK, citing the company's position in the growing cardiac electrophysiology market, experienced management team including former Baylis and Boston Scientific executive Marie-Claude Jacques, and two revenue-generating products with strong clinical evidence.
Catheter Precision (NYSE American:VTAK) has received its first purchase order for LockeT from Montefiore Medical Center in the Bronx, NY. This development follows the company's recent expansion of its US sales and clinical team for LockeT's national product launch. Montefiore, a premier academic medical center and primary teaching hospital of Albert Einstein College of Medicine, performs over 1,000 electrophysiology and cardiac rhythm procedures annually. The medical center is part of the Montefiore Einstein health network, which encompasses over 300 locations including 13 hospitals.
Catheter Precision (NYSE American:VTAK) reported Q3 2024 financial results and operational updates. The company has expanded its pipeline to 87 potential hospital customers, with 32 institutions in evaluation phase. Sales revenue reached $96,000 for Q3 and $271,000 for nine months ended September 30. The company reported a Q3 net loss of $4.1 million, with $1.7 million in non-cash charges. Total assets were $26.7 million with $1.3 million cash position. LockeT CE Mark completion is expected by Q1 2025, with European launch planned for Q2 2025. Clinical studies for both LockeT and VIVO products continue to show promising results.
Catheter Precision (NYSE American:VTAK) presented new clinical data from the VIVO EU Registry at the Society of Cardiac Robotic Navigation meeting in Lisbon. Professor Leonor Parreira shared final data from Hospital da Luz, involving 27 subjects, of which 18 underwent ablation procedures. The results showed 100% accurate identification of site origin, approximately 95% successful ablation procedures, and 83% of patients remained arrhythmia-free at 12 months post-ablation. The company plans to publish complete study results including data from seven additional studies.
Catheter Precision (NYSE American:VTAK) has secured $4.9 million in gross proceeds through warrant exercises. The company entered into a definitive agreement for the immediate exercise of Series E, F, G, H, and I warrants to purchase 5,347,981 shares at a reduced price of $0.70 per share, generating $3.7 million. An additional $1.185 million was received through warrant exercises in the past week. In exchange, the company will issue new unregistered Series K warrants for up to 10,695,962 shares at $0.70, exercisable after shareholder approval with a 5.5-year term.
Catheter Precision (NYSE American:VTAK) announced two presentations featuring their VIVO technology at the International Society for Cardiac Robotic Navigation Meeting in Lisbon, Portugal, October 28-29. Dr. Jack Griffiths from Royal Brompton Hospital will present on 'Robotics in VT plus non-invasive 3D mapping', focusing on time-saving data. Peter van Dam, PhD will discuss 'Non-invasive Mapping Using Individual Anatomy', highlighting VIVO's patient-specific advantages. Dr. Leonor Perriera will present updates from the VIVO European Registry, including acute success and 12-month follow-up data for ventricular ablation.
Catheter Precision, Inc. (NYSE American:VTAK) has announced a new publication in the October 2024 issue of HeartRhythm Case Reports, highlighting the use of their VIVO technology in a novel, non-invasive ablation technique called stereotactic radioablation (STAR). The procedure, which uses external photon beams to target and ablate areas of the heart responsible for arrhythmia, demonstrated success in a patient unresponsive to traditional ablation for ventricular tachycardia.
Key highlights include:
- VIVO played a fundamental role in identifying the VT origin within the scar
- VIVO provided a more precise location than traditional 12-lead ECG methods
- After a 4-month follow-up, the patient reported no new episodes of VT or heart failure
CEO David Jenkins emphasized the potential of VIVO as a non-invasive, patient-specific, pre-procedural planning tool for improving procedural outcomes in non-invasive ablation treatments.
Catheter Precision (NYSE/American:VTAK) announced its participation in the 15th International Symposium on Catheter Ablation Techniques (ISCAT) from October 16-18 in Paris, France. ISCAT is a biannual European meeting focusing on new and emerging catheter ablation technologies, techniques, and study data for atrial and ventricular arrhythmias.
CEO David Jenkins emphasized the importance of attending such meetings as part of their sales strategy, stating that it provides an opportunity to meet physicians, showcase technologies, and generate new sales leads. At ISCAT, Catheter Precision plans to demonstrate their VIVO technology and highlight recent clinical data presented at the European Society of Cardiology meeting in September, which demonstrates VIVO's value and accuracy.
Catheter Precision, Inc. (NYSE/American:VTAK), a US-based medical device company specializing in cardiac electrophysiology products, has announced its participation in the 19th annual International VT Symposium on October 11-12 in New York City. The symposium, hosted by the Hospital at the University of Pennsylvania and Mount Sinai Hospital, focuses on new management strategies for ventricular arrhythmias, including nonpharmacological therapies like implantable devices and catheter ablation techniques.
David Jenkins, CEO of Catheter Precision, emphasized the importance of this event, stating it provides an opportunity to interact with a specialized group of physicians treating ventricular arrhythmias. The company's VIVO product enables better planning of ventricular ablation procedures, potentially reducing procedural time and patient complications. Catheter Precision aims to share new data and product improvements with attendees during the symposium.
Catheter Precision (NYSE/American:VTAK) has announced updates for their VIVO non-invasive mapping system. At the European Society of Cardiology (ESC) meeting, Prof. Tarv Dhanjal presented data from a 20-patient study, showing 90% procedural success at a mean follow-up of 7.3 ± 4.7 months in patients with scar-related VT. The full study, expected to enroll 50 patients, is anticipated to conclude in 2025.
Catheter Precision will showcase VIVO at several conferences in October, including the International VT Symposium, ISCAT, and SCRN. The company is expanding its commercial footprint, with over 25 centers confirming interest and eight new centers scheduled for evaluations. Additionally, following a successful evaluation in Doha, Qatar, the hospital has acquired and installed the VIVO system, completing its first commercial procedures.